GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of ...

GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion.

A drug currently sold under the name Zantac 360 uses a different active ingredient and contains no ranitidine.

UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over ...

The concerns surrounding Zantac also prompted UK health authorities to advise doctors in 2019 to cease prescribing specific formulations of the drug as a precautionary measure. Reports indicated that ...

Zantac 360 Famotidine may also be used for purposes not listed in this medication guide. Heartburn can feel like a heart attack. chest pain that spreads to your jaw or shoulder. Get emergency ...

GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac heartburn remedy causes cancer. The British drugmaker’s settlement ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of ...

Boehringer Ingelheim is the exception. It has not announced any major settlements. A drug under the name of Zantac 360, which contains no ranidine, is still being currently sold.

A drug currently sold under the name Zantac 360 uses a different active ingredient and contains no ranitidine.

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on ...